{
    "nct_id": "NCT05478499",
    "official_title": "A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)",
    "inclusion_criteria": "1. Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator\n2. Deemed by the Investigator to be a candidate for phototherapy or systemic therapy\n3. Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1\n4. ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1\n5. Evidence of plaque psoriasis in a non-scalp area\n6. Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Target Disease Exceptions:\n\n  1. Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}